Introduction
The A 2B adenosine receptor (A 2B AR) is involved in many important physiological and pathophysiological functions, such as the hematopoietic stem cell emergence [1] , inflammation [2] [3] [4] , cell proliferation [5] [6] [7] ; reactive oxygen species (ROS) production [8] , erectile function [9] , bone homeostasis [10] , cardiac protection [11] and diabetes mellitus [12] . However, the signaling mechanisms related to those functions are not well understood. In particular, the mechanisms leading to ERK1/2 phosphorylation, one of those canonical signaling processes, have not been well explored and currently published data are inconsistent. For example, it has been suggested A 2B AR-mediated ERK1/2 activity in HEK293 cells is via the Gq/11 protein [13] . However, Schulte and Fredholm [14] suggested that A 2B AR-mediated ERK1/2 activity in CHO cells expressing the recombinant A 2B AR is mediated via Gs rather than Gq/11. Epperson et al. [15] also found a lack of A 2B AR-coupling to Gq protein in cardiac fibroblasts. PKC is a typical modulator of the A 2B AR-and other GPCR-mediated ERK1/2 activity [16] . However, Fang and Olah [17] showed that EPAC1 but not PKC is involved in A 2B AR-mediated ERK1/2 phosphorylation in human vascular endothelial cells (HUVEC). In rat skeletal muscle, A 2B AR activation was found not to modulate ERK1/2, although it stimulated cAMP accumulation [18] . In trophoblast cells, it was found that A 2B AR downregulates ERK1/2 activity [19] . ERK1/2 activity stimulated by adenosine-5 0 -N-ethyluronamide (NECA) in A 2B ARexpressing CHO is via PI3K, but not PKA [14] . However, Sun et al. [20] showed that A 2B AR activation stimulates ERK1/2 activity via PKA in sickle erythrocytes. Thus, it seems signal mechanisms diverge in various studies and in different cell types under different conditions. Indeed, A 2B AR has been shown to cause both proliferation and antiproliferation in different cell types [5, [21] [22] [23] [24] [25] [26] [27] . A 2B AR has been reported to involve both pro-and anti-inflammatory actions [2, [28] [29] [30] , which might be related the different G protein-coupling in different types of immune cells. Thus, it is important to understand the types of G proteins or signaling pathways involved in A 2B AR-mediated functions.
Recent studies show that various A 2B AR agonists have different maximum effect (Emax) and signaling bias in different signaling pathways [31, 32] . Nonnucleoside agonist BAY60-6583 stimulates ERK1/2 activity in HEK293 cells but not in T24 bladder cancer cells, both endogenously expressing the A 2B AR, although nucleosides NECA and adenosine-5 0 -N-cyclopropyluronamide (CPCA) stimulated ERK1/2 activity in both cell types [31] . It was demonstrated that BAY60-6583 behaves as an antagonist and induces insulin secretion in a mouse pancreatic cell line, MIN-6 [31] . Some controversies concerning the A 2B AR might also be due to different agonists used in those earlier studies.
In the present study, we explore the coupling of the native human A 2B AR to Gi, Gq/11 and Gs in three different cell types, 1321 N1 astrocytoma, HEK293, and T24 bladder cancer cells. We used NECA and BAY60-6583, selective blockers for Gi, Gs and Gq/11, as well as the clustered regularly interspaced short palindromic repeat-associated protein-9 nuclease (CRISPR/Cas9)-based Gq/11-and Gs-null HEK293 cells [33, 34] . As ERK1/2 activity and calcium mobilization are involved in many A 2B -mediated functions and are the convergence of multiple G protein-signaling pathways directed under the A 2B AR, we explored the contributions of various G proteins and downstream signaling molecules to ERK1/2 activity and calcium mobilization. These pathways were compared in three different cell types endogenously expressing almost solely the A 2B AR with the other three AR subtypes being at very low levels. We found that the A 2B AR may couple to different downstream signaling events via different G proteins in the same cell type, and the A 2B AR may couple to the same downstream pathway via different G proteins in different cell types. Gi and Gs proteins activated by the A 2B AR may play opposing or synergistic roles in different cell types and in different signaling pathways. Any one of the three G proteins, Gi, Gq/11, and Gs, may be solely responsible for a specific signaling event mediated via the A 2B AR depending on cell type. The findings could be related to controversial roles of the A 2B ARmediated effects reported in literature, e.g. proliferation and antiproliferation, or proinflammatory vs. anti-inflammatory. These findings could be applicable to the study of signaling pathways of other GPCRs, and should be of considerable relevance to future drug discovery and development. GO6983, CE3F4, ESI-09, HJC0350, H89, PSB603,  NECA (adenosine-5 0 -N-ethyluronamide) and MRS2365 ([[(1R,2R,3S,4R,5S) 
Materials and methods

Materials
diphosphoric acid monoester trisodium salt) were from Tocris (Ellisville, MO). CGS21680, Carbachol, CTX and PTX were from Sigma (St. Louis, MO). UBO-QIC was purchased from University of Bonn (Bonn, Germany). BAY60-6583 (LUF6210, termed hereafter 'BAY') was synthesized at Leiden/Amsterdam Center for Drug Research and was provided by Ad IJzerman (Leiden, The Netherlands). MRS3997 [35] and MRS5911 [36] were synthesized at NIDDK, National Institutes of Health (Bethesda, MD, USA), and were provided by H. Adachi 
ERK1/2 stimulation
The method used was as previously described [37] . HEK293 cells, 1321 N1 astrocytoma cells or T24 bladder cancer cells endogenous expressing the A 2B AR were seeded in a 96-well plate in complete growth medium. After cell attachment, medium was removed and cells were serum-starved overnight in 90 ml serum free medium. To examine the time-course, cells were stimulated with agonists at various time points. To obtain agonist concentration-response curves, HEK293 and T24 cells were stimulated for 5 min, and 1321 N1 cells were stimulated for 10 min. Cells were pretreated with an antagonist or inhibitor 30 min (except that cells were pretreated with PTX (200 ng/ml) or CTX (500 ng/ml) overnight) before the addition of an agonist. After agonist treatment, the medium was removed and cells were lysed with 1Â lysis buffer (20 ml) (PerkinElmer AlphaScreen SureFire Ò p-ERK1/2 (Thr202/Tyr204) Assay Kit). Lysate (4 ml/well) was transferred to a 384-well ProxiPlate Plus Ò (PerkinElmer, Waltham, MA).
Acceptor beads were diluted 1:50 in a 1:5 mixture of activation buffer in the reaction mixture and added to the 384-well plate (5 ml/ well). The plate was sealed and incubated for 2 h at room temperature. Donor beads (2 ml) diluted 1:20 in dilution buffer were added, and the plate was incubated for another 2 h at room temperature. The plate was measured using an EnVision Ò multilabel reader using standard AlphaScreen Ò settings as instructed by the manual.
Intracellular calcium mobilization
HEK293 cells, 1321 N1 astrocytoma cells or T24 bladder cancer cells endogenously expressing the A 2B AR were grown overnight in 100 ll of media in 96-well black plates at 37°C and 5% CO 2 . Cells were washed with Hank's Buffer containing 20 mM HEPES (pH 7.4; without calcium and magnesium). The calcium 6 assay kit was used as instructed by mixing Hank's Buffer containing 20 mM HEPES without calcium and magnesium. Probenecid (final concentration of 2.5 mM) was added to the loading dye to increase dye retention. Cells were incubated with 100 ll dye/probenecid for 60 min at room temperature. Cells were pretreated with various concentrations of antagonists for 30 min or PTX (200 ng/ml) overnight before the addition of agonists. All reagents used were prepared using Hank's Buffer containing 20 mM HEPES. Samples were run in duplicate or triplicate using a FLIPR TETRA Ò (Molecular Devices, Sunnyvale, CA) at room temperature. Cell fluorescence (excitation at 485 nm; emission at 525 nm) was monitored following exposure to A 2B AR agonists. Increases in intracellular calcium concentrations are reported as the maximum fluorescence value after exposure minus the basal fluorescence value.
Data analyses
Data were analyzed using Prism Ò 7.0 software (GraphPAD, San Diego, CA). Statistical significance of the differences was assessed using Student's t test (between two conditions) or a One-Way Analysis of Variance (ANOVA) followed by Bonferroni's or Turkey's multiple comparison tests where appropriate among multiple conditions. Differences yielding P < .05 were considered as statistically different.
Results
Gene expression of four AR subtypes in three cell types
In order to study the coupling of the endogenous human A 2B AR to different G proteins, we selected three cell types, HEK293, T24 and 1321 N1, which endogenously express the A 2B AR highly in comparison to the other three AR subtypes. The reason for our use of AR agonist NECA is that it is still the only established full agonist for the A 2B AR that is commercially available, although nonselective. The nonnucleoside agonist BAY60-6583 is a partial agonist, albeit selective. Previously, we have found that the A 2B AR is highly expressed in HEK293, 1321 N1 and T24 cells at a similar expression level [31] . However, the expression level of the A 2B AR has not been strictly compared with that of the other three AR subtypes. Thus, in the present study we compared the expression patterns of the four ARs at these three cell lines. The gene expression of the A 2B AR was found consistent with A 2B AR agonist-induced cAMP accumulation in those three types of cells and several other types of cells [31] . Fig. 1 shows that A 2B AR was the dominant AR in comparison to other ARs in all three cell types, which were used in subsequent experiments.
Coupling of the A 2B AR to Gs, Gq and Gi in HEK293 cells
Cyclic AMP accumulation in HEK293 cells
Although Fig. 1a shows that the A 2B AR is expressed at a much higher level compared with the other three ARs, to assure that the effect of NECA is solely via the A 2B AR, not the A 2A AR, both of which couple to Gs, we examined the potential effect of the A 2A ARselective agonist CGS21680 and tested the effect a selective A 2B AR antagonist PSB603 on NECA-stimulated cAMP accumulation in HEK293 cells. Fig. 2a shows that CGS21680 has negligible effect in comparison to NECA. The A 2B AR-selective antagonist PSB603 at the concentration of 10 nM rightward shifts the NECA concentration-response curve to the right in a parallel manner, suggesting the effect of NECA is indeed solely via the A 2B AR.
We next examined NECA-induced cAMP accumulation in Gsnull HEK293 cells generated previously using CRISPR/Cas9 [34] . As a comparison, we also tested the effect of NECA in Gq-null HEK293 cells [37] . Fig. 2b shows that NECA-induced cAMP accumulation was completely eliminated by Gs knockout (KO), but unaffected by Gq/11 KO. The effect of BAY was also completely diminished by Gs KO (Fig. 2c) , but not by Gq/11 KO, UBO-QIC or PTX (data not shown).
A 2B AR-mediated ERK1/2 activity in HEK293 cells
In the following experiments (Fig. 3) , we examined the G proteins possibly involved in A 2B AR-mediated ERK1/2 activity in HEK293 cells. NECA (3 lM) induced stimulation of ERK1/2 activity in HEK293 typically 3-5-fold above basal value, reaching maximum at 5 min. The PKC inhibitor GO6983 completely eliminated the effect of NECA and diminished basal activity. The Gq/11 inhibitor UBO-QIC had a negligible effect, whereas both CTX and PTX significantly inhibited the effect of NECA at 5 min (Fig. 3a) , suggesting that both Gs and Gi, but not Gq/11, are involved in NECA-induced ERK1/2 phosphorylation. The inhibition of ERK1/2 activity by PTX and GO6983 suggests that A 2B AR-mediated ERK1/2 activity is at least partly via bc release from Gi/o and subsequent activation of the PLC-PKC pathway, although crosstalk between intracellular second messenger systems and the activation of PKC by downstream pathways other than Gq/11 is also possible. Fig. 3b shows that NECA induced increases of ERK1/2 activity in control HEK293 cells and Gq/11-null HEK293 cells, but not in Gsnull HEK293 cells, further confirming that Gs but not Gq/11 plays a major role in ERK1/2 activity mediated via the endogenous A 2B AR. As a control, both UBO and Gq/11 KO diminished ERK1/2 activity stimulated by the P2Y 1 receptor-selective agonist MRS2365 (Fig. 3c) . To confirm the involvement of Gi proteins in NECA-induced ERK1/2 activity, PTX was applied to Gq/11-null HEK293 cells. Fig. 3d shows that similar to the control HEK293 cells, PTX but not UBO significantly diminished the effect of NECA. The ERK1/2 activity stimulated by NECA at 5 min in the presence of PTX was significantly different from the control (p < .05). UBO did not affect NECA-stimulated ERK1/2 activity in Gq/11-null HEK293 cells (p > .05 compared with control).
As both PKA and EPAC are possibly involved in Gs-mediated events, we next examined the steps downstream of Gs mediating ERK1/2 activity. Fig. 4e shows that the adenylyl cyclase activator forskolin and the A 2B AR agonist NECA stimulate ERK1/2 activity to a similar extent, and the effect of NECA was diminished 48 ± 6% by the PKA inhibitor H89, and 92 ± 5% by the nonselective EPAC inhibitor ESI-09 [39] . This suggested that both PKA and EPACs are downstream of Gs-mediated ERK1/2 activity in HEK293 cells, and EPACs probably play a major role in this event. It remains to be examined whether EPAC1 or EPAC2 plays a more significant role in A 2B AR-mediated ERK1/2 activity.
As described above, Gi and Gs but not Gq/11 are involved in endogenous A 2B AR-stimulated ERK1/2 activity. We were curious if the expression level of the A 2B AR may or may not affect G protein-coupling, as cells overexpressing the recombinant A 2B AR were used in many previous studies [14, 40] . Fig. 3f shows that overexpression of the A 2B AR in HEK293 cells led to a dramatic increase in NECA-induced ERK1/2 activity. In HEK293 cells expressing the recombinant A 2B AR, forskolin only induced a 4-fold increase of ERK1/2 activity, whereas NECA induced a > 40-fold increase of ERK1/2. Interestingly, UBO, which did not affect NECA-induced ERK1/2 activity in control HEK293 cells, induced a modest but significant decrease with A 2B AR overexpression (28 ± 5%; P < .05 compared with NECA group). On the other hand, both CTX and PTX induced a > 70% inhibition of ERK1/2 activity in control HEK293 cells, but only about 50% inhibition in HEK293 cells overexpressing the recombinant A 2B AR. Thus, G protein-coupling patterns of the A 2B AR in the overexpressed cells may not accurately represent the coupling of the native A 2B AR. Fig. 4a shows that NECA only induced a slight increase of intracellular calcium (about 10-15% compared with that induced by the selective P2Y 1 receptor agonist MRS2365 (Fig. 4b) ). However, neither NECA nor MRS2365 induced calcium transients in Gq/11-null HEK293 cells (Fig. 4a and b) .
A 2B -mediated intracellular calcium mobilization in HEK293 cells
As NECA only induced a small increase in calcium transients in control HEK293 cells, we further tested this in HEK293 cells overexpressing the recombinant A 2B AR. Fig.3c shows that NECA induced a robust calcium response in HEK293 cell overexpressing the A 2B AR but not in Gq/11-null HEK293 cells overexpressing the A 2B AR. Also, the Gq/11 inhibitor UBO completely inhibited the effect of NECA.
Comparing Fig. 4a and c, it was noted that the A 2B ARoverexpression increased the NECA-induced calcium response, and the signal-to-noise ratio increased $ 5-fold. However, the Fig. 3 . Stimulation of ERK1/2 activity in HEK293 cells. A. Effect of Gq/11 inhibitor UBO-QIC, Gi inhibitor PTX, Gs down-regulator CTX and PKC inhibitor GO (GO6983) on NECAstimulated ERK1/2 activity. Cells were pretreated with UBO-QIC and GO6983 for 30 min or PTX and CTX overnight before the addition of agonist. #Significantly different from control (NECA) (P < .05, One-Way ANOVA followed by post hoc test (Bonferroni)). B. NECA-stimulated ERK1/2 activity in Gs-and Gq/11-null HEK293 cells. C. ERK1/2 activity stimulated by the agonist MRS2365 of the Gq/11-coupled P2Y 1 receptor. D. ERK1/2 activity in Gq/11-null HEK293 cells. E. Comparison of ERK1/2 activity induced by the adenylyl cyclase activator forskolin and A 2B AR (nonselective) agonist NECA (expressed as 100%), and the inhibition of PKA inhibitor H89 and nonselective EPAC inhibitor ESI-09 on the effect of NECA. F. Comparison of the effects of forskolin and NECA in HEK293 cells overexpressing the A 2B AR (HEK293-A2B), and the effects Gi, Gs, and Gq/11 inhibitors on NECA-stimulated ERK1/2 activity. # Significantly different from control (NECA) (P < .05, One-Way ANOVA followed by post hoc test (Bonferroni)). Data are mean ± SD from three independent experiments performed in triplicate.
potencies of NECA in control HEK293 and in HEK293-A 2B AR cells were found not significantly different (385 ± 86 vs. 496 ± 138 nM, P > .05, unpaired t-test). Similarly, potencies of NECA to induce ERK1/2 activity in control HEK293 cells and in HEK293-A 2B AR cells (475 ± 66 vs. 561 ± 122 nM) were also not significantly different (P > .05, unpaired t-test). Fig. 5a shows the raw ERK1/2 activity data; Fig. 5b shows the normalized data. However, A 2B AR overexpression significantly increased the potency (over 100-fold) rather than the Emax of NECA in stimulation of cyclic AMP accumulation (Fig. 5c) . Thus, A 2B AR overexpression changed coupling efficiency differently at different signaling pathways, i.e. it may change agonist Emax or agonist potency depending on the signaling pathway measured.
Coupling of the A 2B AR to Gs, Gi and Gq/11 in T24 bladder cancer cells
We demonstrated previously that NECA-induced cAMP accumulation in T24 cells is exclusively via the A 2B AR [31] . NECA also induced a robust response in calcium mobilization and ERK1/2 phosphorylation. However, the G proteins or signaling molecules involved in those events have not been explored. In the following experiments, we examined the G proteins that potentially mediate those signaling events. Fig. 6 shows that both NECA and BAY induced robust cAMP accumulation, which was not affected by PTX and/or UBO-QIC, suggesting neither Gi or Gq/11 proteins have an impact on A 2B ARmediated cAMP accumulation in T24 cells under normal conditions. Fig. 7a shows that NECA induced a maximum stimulation of ERK1/2 activity of 2-to 3-fold above basal value at about 5 min. Similar to that in HEK293 cells, the PKC inhibitor GO6983 eliminated NECA-induced ERK1/2 activity and diminished basal ERK1/2 activity in T24 cells. Interestingly, unlike that in HEK293 cells, NECA-stimulated ERK1/2 activity was completely blocked by PTX, but was significantly enhanced by CTX, suggesting Gs and Gi play opposing roles in A 2B AR-mediated ERK1/2 phosphorylation in T24 cells. The effect of UBO was negligible. To confirm this, we ran a concentration response curve of NECA in the absence or presence of UBO. Fig. 7b shows that UBO mainly affected the basal ERK1/2 activity, without affecting the potency of NECA. Fig. 7c shows that the concentration-response of NECA was enhanced and diminished by CTX and PTX, respectively. The results suggest that Gi proteins solely mediate a strong A 2B AR-stimualted ERK1/2 activity, however, under normal conditions, a large part of the stimulatory effect of A 2B AR is masked by Gs.
A 2B -mediated cAMP accumulation in T24 bladder cancer cells
A 2B -mediated ERK1/2 activity in T24 bladder cancer cells
We further explored the pathways downstream of Gs that mediates the inhibitory effect on ERK1/2 activity. Fig. 7d shows that forskolin significantly diminished whereas NECA stimulated ERK/12 activity in T24 cells, suggesting that the role of Gs is probably opposite to that in HEK293 cells (Fig. 4e) . The effect of NECA was significantly enhanced by both the PKA inhibitor H89 and the EPAC2 inhibitor HJC0350 [41] , but not by the EPAC1 inhibitor CE3F4 [42] .
As shown earlier [31] in T24 cells, only NECA stimulated ERK1/2 activity (about 2-fold above basal value), whereas the nonnucleoside agonist BAY did not increase ERK1/2 activity, which was thought to be presumably due to the partial agonist activity of BAY. In the present study, we further examined the role of Gs in this lack of ERK1/2 stimulation by BAY. Fig. 7e shows that indeed BAY does not stimulate ERK1/2 activity. However, in the presence of CTX, BAY induced a robust increase (3-fold) of ERK1/2 activity. Thus, the previous observation that BAY did not stimulate ERK1/2 activity in T24 cells is due to the fact that Gs masks the stimulatory effect of the A 2B AR.
A 2B -mediated intracellular calcium mobilization in T24 bladder cancer cells
Unlike in HEK293 cells, activation of the native A 2B AR induced a robust increase of intracellular calcium. Fig. 8 shows that NECAinduced calcium increase is almost completely diminished by PTX, and also significantly affected by CTX, but not influenced by UBO-QIC, suggesting that calcium mobilization in T24 cells is mostly mediated via Gi proteins, and to a lesser extent by Gs, but not via the Gq/11 proteins. NECA concentration-dependently induced cAMP accumulation in 1321 N1 astrocytoma cells endogenously expressing the A 2B AR, which was not significantly affected by the Gi inhibitor PTX or the Gq/11 inhibitor UBO (Fig. 9) .
A 2B AR suppressed ERK1/2 activity in 1321 N1 astrocytoma cells
Unlike the role of the native A 2B AR in HEK293 and T24 cells which increases ERK1/2 activity, the activation of the A 2B AR in 1321 N1 astrocytoma cells diminished rather than stimulated ERK1/2 activity. The suppressing effect of NECA reached a maximum at about 5-10 min, and the suppression lasted for at least 60 min. Fig. 10 shows the time course of NECA-induced and the A 2B AR-mediated suppression of ERK1/2 activity.
As described above, the suppression of ERK1/2 activity mediated via the A 2B AR in 1321 N1 astrocytoma cells reached a maximum at 5-10 min, thus in the following experiment, the stimulation time was selected as 10 min. The decrease by NECA was partially reversed by CTX, further diminished by PTX, but not affected by UBO (Fig. 10b) , suggesting a Gs-mediated mechanism. CTX and PTX significantly increased and decreased the effect of NECA, respectively (P < .05, compared with NECA group; OneWay Analysis of Variance (ANOVA) followed by post-test (Bonferroni)). Fig. 10c shows that both forskolin and NECA diminish ERK1/2 activity in 1321 N1 astrocytoma cells, and forskolin actually produced an effect larger than that of NECA (P < .05, unpaired t-test). The effect of NECA was partially reversed by H89 and further decreased by EPAC1 inhibitor CE3F4, but it was not affected by EPAC2 inhibitor HJC0350. This suggested that PKA is at least partially responsible for NECA-induced decrease of ERK1/2 activity in 1321 N1 astrocytoma cells, and EPAC1 plays a role that is the opposite of PKA. The decreased ERK1/2 activity by NECA was further decreased by GO6983, but completely reversed by the selective A 2B AR antagonist PSB603.
We have shown previously [31] that NECA is a full agonist, whereas BAY, MRS5911 and MRS3997 are partial agonists in stimulation of ERK1/2 activity in HEK293 cells. Here, Fig. 10d shows that all agonists concentration-dependently decreased ERK1/2 Fig. 7 . A 2B AR agonist-stimulated ERK1/2 activity in T24 bladder cancer cells. A. Effect of Gq/11 inhibitor UBO-QIC, Gi inhibitor PTX, Gs down-regulator CTX and PKC inhibitor GO (GO6983) on NECA-stimulated ERK1/2 activity. Cells were pretreated with UBO-QIC and GO6983 for 30 min or PTX and CTX overnight before the addition of agonist. B. concentration-response curves of NECA in the presence and absence of UBO (UBO-QIC). C. Concentration-response curves of NECA in the presence and absence of PTX and CTX (the Emax of NECA in the absence of CTX or PTX was expressed as 100%). D. Comparison of forskolin-and NECA-stimulated ERK1/2 activity, and the effects of PKC inhibitor GO6983 (10 lM), PKA inhibitor H89 (10 lM) and EPAC1 inhibitor CE3F4 (10 lM) and EPAC2 inhibitor HJC0530 (3 lM). Control and NECA + GO groups were expressed as 100% and 0%, respectively. *Significantly different from control (P < .05). # significantly different from NECA group (P < .05). E. Effect of downregulation of Gs by CTX on the ERK1/2 activity stimulated by the nonnucleoside agonist BAY60-6583. Each data point represents the mean ± SD from three independent experiments in triplicate. activity in 1321 N1 astrocytoma cells, with NECA being more efficacious than BAY and MRS3997 in suppressing the ERK1/2 activity.
A 2B AR activation fails to stimulate intracellular calcium mobilization in 1321 N1 astrocytoma cells
Unlike in T24 cells, activation of the A 2B AR in 1321 N1 astrocytoma cells did produce any intracellular calcium mobilization (Fig. 11) . As a control, carbachol produced a robust response via the activation of native muscarinic receptors.
Discussion
By using three cell types, HEK293 (including wild-type, Gs-and Gq/11-null HEK293), 1321 N1 astrocytoma and T24 bladder cancer cells, it was demonstrated in the present study that the endogenous A 2B AR may couple to the same downstream signaling pathway via different G proteins in different cell types, and it may couple to different signaling pathways via different G proteins in the same type of cells (Table 1) . Furthermore, Gs and Gi may have both opposing effects and synergistic effects in mediating downstream events, depending on cell type and signaling pathway. This could be a reason for the A 2B AR displaying both proliferative and antiproliferative effects in different cell types [5, [21] [22] [23] [24] . It could also be related to the proinflammatory and anti-inflammatory roles of the A 2B AR in different types of inflammatory cells or different functions of the same cell types [2, [28] [29] [30] . It remains to be explored how the ubiquitous A 2B AR couples to G proteins and downstream signaling events in other cell types and interacts with adenosine signaling via other ARs in the same cell type, considering the important adenosinergic functions throughout the body. Also, differential signaling of the A 2B AR in other peripheral tissues (e.g. cardiac and vascular tissue) versus CNS regions, and signaling changes in disease states deserve further exploration. The potential Gi coupling could also explain the cardioprotective effects of the A 2B AR [43, 44] . The differential signaling observed here for the A 2B AR raises concerns regarding the reliability of in vitro data as it relates to drug discovery in general.
The possibility of a GPCR coupling to multiple G proteins has been proposed previously, including for b 2 and b 3 adrenergic [45, 46] ; luteinizing hormone [47] , follicle stimulating hormone [48] , d-opioid [49] , and cannabinoid CB1 [50] receptors. It has been suggested that FMRFamide-related mixed action in vivo might be related to dual Gi/Gs coupling, based on studies using PTX and CTX [51] . The coupling to multiple G proteins has been the best characterized for the b 2 receptor, including the demonstration that both Gi and Gs pathways under the b 2 receptor are involved in heart function [52] [53] [54] . However, the nature of dual coupling has not been explored previously by strictly comparing the native receptors in different cell types. The mechanisms behind this Gi-Gs dual coupling phenomenon have been controversial. For example, a possibility of ligand-specific coupling of b 2 receptor to G proteins was suggested [54] . PKA phosphorylation of receptor might switch the b 2 receptor coupling from Gs to Gi [55] . Hill and Baker [56] proposed that expression levels and locations of G proteins and receptors in the cell membrane, rather than phosphorylation by PKA are responsible for the Gi coupling. Crespo et al. [57] suggested that b 2 -mediated MAPK activation in COS-7 cells is via G protein bc subunits. It has also been indicated that b 2 receptor coupling to Gi is indirect and dependent on A 1 AR [58] .
However, the mechanisms inferred from many earlier studies were from the use of transfected cell lines, and may not represent the mechanisms in native cells. Furthermore, the coupling to different G proteins has not been strictly compared in different cell types, which could have different expression levels of receptors and G proteins, as well as different locations of G proteins in different membrane microdomains. With the recent availability of the selective Gq/11 inhibitor UBO-QIC [37, 59] and Gs-and Gq/11-null HEK293 cells generated using CRISPR/Cas9 [34, 37, 60] , we were able to compare the G protein-coupling unambiguously. For example, intracellular calcium mobilization in HEK293 cells was completely eliminated by either Gq/11 KO or by UBO suggesting Gq/11-mediated mechanism; In T24 cells, the calcium increase was significantly diminished by PTX but not by UBO, suggesting a Gi-mediated mechanism. Also, by using both HEK293 cells and the Gq/11-null HEK293 cells, we were able to observe the diminishing effect of PTX on NECA-stimulated ERK1/2 activity, clearly suggesting a Gi-but not Gq/11-mediated mechanism.
It has been well documented that in addition to PKA, EPACs, also downstream mediators of Gs, are critical in many signaling cascades [61] [62] [63] . However, the role of the EPACs in A 2B AR signaling has not been well documented. In the present study, we found that EPACs have different roles in different cell types and in different signaling pathways. For example, in HEK293 cells, A 2B ARmediated ERK1/2 activity is via Gs followed by both PKA and EPACs; in T24 cells, both PKA and EPAC2, but not EPAC1, inhibit Gs-mediated suppression of ERK1/2 activity. In 1321 N1 cells, EPAC1 and PKA have opposing role in A 2B AR-mediated ERK1/2 activity, whereas EPAC2 plays a negligible role. These pathways remain to be examined in other cell types. As A 2B AR activation may only lead to a Gi-dependent signaling event that is relevant to a specific condition (e.g. ERK1/2 activity in T24 cells) or to Gs-dependent signaling (ERK1/2 activity in1321N1 cells), it is important to understand the signaling mechanisms including the G proteins involved in a specific disease. Receptorselective drugs may not have sufficient specificity for certain specific conditions, as they may produce both Gi and Gs signaling events.
Cell type-specific or G protein-coupling specific agonists for the A 2B AR in theory could produce fewer side effects, considering the ubiquitous presence and the important functions of the A 2B AR. Selectively enhancing a specific A 2B AR signaling pathway may be a useful strategy for the treatment of heart failure [64] . On the other hand, it is possible that the balance between Gi and Gs coupling might be required for a particular physiological response, considering the ubiquitous presence of adenosine throughout the body. Adenosine is released under stress conditions, the imbalanced response of the A 2B AR in different cells or tissues and the balanced Gi-Gs coupling within the same type of cells may represent fine-tuned AR systems.
Considering the impact of ERK and calcium in many important cell functions such as cancer drug addiction, cell proliferation and insulin secretion [24, 65, 66] , it is important to consider both activation or inhibition of the A 2B AR based on the cell types and the relevant pathophysiological conditions. For example, A 2B AR activation may have both proliferative and antiproliferative effects depending on cell types [5, [21] [22] [23] [24] . A 2B AR signaling has also been Fig. 10 . A 2B AR-mediated ERK1/2 activity in 1321 N1 astrocytoma cells. A. Time-course of NECA-suppressed ERK1/2 activity. B. Effect of Gq/11 inhibitor UBO-QIC, Gi inhibitor PTX and Gs downregulator CTX on NECA-suppressed ERK1/2 activity. Cells were pretreated with UBO-QIC for 30 min or PTX and CTX overnight before the addition of agonist and incubated for another 10 min. *Significantly different from control (P < .05). #Significantly different from NECA group (P < .05). C. Comparison of the suppression of ERK1/ 2 activity by adenylyl cyclase stimulator forskolin and agonist NECA, and the effects of PKA and EPAC inhibitors on NECA-induced suppression of ERK1/2 activity. Control and NECA + GO groups were expressed as 100% and 0%, respectively. *Significantly different from control (P < .05, unpaired t test).
# Significantly different from NECA group (P < .05, One-Way ANOVA followed by post hoc test (Bonferroni)). D. Concentration-response of ERK1/2 activity suppressed by four A 2B AR agonists. Results are expressed as mean ± SD from at least three independent experiments performed in duplicate or triplicate. suggested to induce different types of cardioprotection in a tissuedependent way [67] . In summary, A 2B AR may couple to the same downstream signaling pathway via different G proteins in different cell types, and it may couple to different signaling pathways via different G proteins in the same type of cells. Any one of the three G proteins, Gi, Gq/11, or Gs, may be solely responsible for a specific signaling event mediated via the A 2B AR depending on cell type. Furthermore, Gs and Gi may have both opposing effects and synergistic effect in mediating downstream events depending on cell type and signaling pathway. The findings could be related to controversial roles of the A 2B AR reported in literature, e.g. proliferation and antiproliferation. This could also be a reason for the A 2B AR to induce both proinflammatory and anti-inflammatory effects in different types of inflammatory cells or different functions of the same cell types. It remains to be explored how the A 2B AR couples to G proteins and downstream signaling events in other cell types, considering the important functions of the A 2B AR is involved and the ubiquitous presence of the A 2B AR throughout the body. The balance of Gi-Gs coupling in one cell type may be of important physiological relevance, and the imbalance of Gi-Gq-Gs coupling among various cell types, tissues and organs should be considered for disease treatment. It remains to be examined whether other GPCRs behave in a similar way or not, as strict comparisons among cell types and signaling pathways, and multiple agonists with diverse chemical structures in native cell systems are rare in the literature. 
